A Randomized, Prospective Trial of 2-6 Weeks Pre-Operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer: Anastrozole +/- Fulvestrant or Tamoxifen Exposure - Response in Molecular Profile (AFTER-Study)

Status: Suspended

Phase of Trial: Phase II

Latest Information Update: 25 Jan 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anastrozole (Primary) ; Fulvestrant (Primary) ; Tamoxifen
Indications Adenocarcinoma; Early breast cancer
Focus Therapeutic Use
Acronyms AFTER

Most Recent Events

20 Jan 2021 Planned End Date changed from 1 Jun 2020 to 1 Jun 2024.
20 Jan 2021 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2022.
20 Jan 2021 Status changed from recruiting to suspended due to preparation for an amendment.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight